Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

ClinicalTrials.gov ID: NCT01399918

Public ClinicalTrials.gov record NCT01399918. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 7:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Trial of Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to find out what effects, good and/or bad the combination of two medications, everolimus and bevacizumab, has on kidney cancer. In this clinical trial we are now testing these medications in combination. We think that both together might work better that either drug alone. Importantly, both of these drugs together have been tested in patients with a different type of kidney cancer and patients tolerated the combination well.

Study identification

NCT ID
NCT01399918
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
57 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 2011 (Type not available)
Primary completion
Dec 28, 2020 (Actual)
Completion
Dec 28, 2020 (Actual)
Last update posted
Feb 1, 2022

2011 – 2020

United States locations

U.S. sites
7
U.S. states
2
U.S. cities
6
Facility City State ZIP Site status
Memorial Sloan Kettering at Basking Ridge Basking Ridge New Jersey 07920 —
Memorial Sloan Kettering Cancer Center at Basking Ridge Basking Ridge New Jersey 07939 —
Memorial Sloan Kettering Monmouth Middletown New Jersey 07748 —
Memorial Sloan Kettering Cancer Center @ Suffolk Commack New York 11725 —
Memorial Sloan Kettering Westchester Harrison New York 10604 —
Memorial Sloan Kettering Cancer Center New York New York 10065 —
Memorial Sloan Kettering at Mercy Medical Center Rockville Centre New York — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01399918, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 1, 2022 · Synced Oct 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01399918 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →